Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients

J. Horak, A. Dolnikova, O. Cumaogullari, A. Cumova, N. Navvabi, L. Vodickova, M. Levy, M. Schneiderova, V. Liska, L. Andera, P. Vodicka, A. Opattova

. 2022 ; 12 (-) : 959407. [pub] 20221017

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22031515

Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pathways are significantly involved in the mechanisms of chemoresistance. MRE11, a part of the MRN complex involved in double-strand break (DSB) repair, is connected to colorectal cancer (CRC) patients' prognosis. Our previous results showed that single-nucleotide polymorphisms (SNPs) in the 3' untranslated region (3'UTR) microRNA (miRNA) binding sites of MRE11 gene are associated with decreased cancer risk but with shorter survival of CRC patients, which implies the role of miRNA regulation in CRC. The therapy of colorectal cancer utilizes oxaliplatin (oxalato(trans-l-1,2-diaminocyclohexane)platinum), which is often compromised by chemoresistance development. There is, therefore, a crucial clinical need to understand the cellular processes associated with drug resistance and improve treatment responses by applying efficient combination therapies. The main aim of this study was to investigate the effect of miRNAs on the oxaliplatin therapy response of CRC patients. By the in silico analysis, miR-140 was predicted to target MRE11 and modulate CRC prognosis. The lower expression of miR-140 was associated with the metastatic phenotype (p < 0.05) and poor progression-free survival (odds ratio (OR) = 0.4, p < 0.05). In the in vitro analysis, we used miRNA mimics to increase the level of miR-140 in the CRC cell line. This resulted in decreased proliferation of CRC cells (p < 0.05). Increased levels of miR-140 also led to increased sensitivity of cancer cells to oxaliplatin (p < 0.05) and to the accumulation of DNA damage. Our results, both in vitro and in vivo, suggest that miR-140 may act as a tumor suppressor and plays an important role in DSB DNA repair and, consequently, CRC therapy response.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031515
003      
CZ-PrNML
005      
20230127131210.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.959407 $2 doi
035    __
$a (PubMed)36324569
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Horak, Josef $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients / $c J. Horak, A. Dolnikova, O. Cumaogullari, A. Cumova, N. Navvabi, L. Vodickova, M. Levy, M. Schneiderova, V. Liska, L. Andera, P. Vodicka, A. Opattova
520    9_
$a Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pathways are significantly involved in the mechanisms of chemoresistance. MRE11, a part of th $a Cancer therapy failure is a fundamental challenge in cancer treatment One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells DNA damaging agents are frequently used in first line chemotherapy regimens and DNA damage response and DNA repair pathways are significantly involved in the mechanisms of chemoresistance MRE11 a part of the MRN $a Cancer therapy failure is a fundamental challenge in cancer treatment. One of the most common reasons for therapy failure is the development of acquired resistance of cancer cells. DNA-damaging agents are frequently used in first-line chemotherapy regimens and DNA damage response, and DNA repair pathways are significantly involved in the mechanisms of chemoresistance. MRE11, a part of the MRN complex involved in double-strand break (DSB) repair, is connected to colorectal cancer (CRC) patients' prognosis. Our previous results showed that single-nucleotide polymorphisms (SNPs) in the 3' untranslated region (3'UTR) microRNA (miRNA) binding sites of MRE11 gene are associated with decreased cancer risk but with shorter survival of CRC patients, which implies the role of miRNA regulation in CRC. The therapy of colorectal cancer utilizes oxaliplatin (oxalato(trans-l-1,2-diaminocyclohexane)platinum), which is often compromised by chemoresistance development. There is, therefore, a crucial clinical need to understand the cellular processes associated with drug resistance and improve treatment responses by applying efficient combination therapies. The main aim of this study was to investigate the effect of miRNAs on the oxaliplatin therapy response of CRC patients. By the in silico analysis, miR-140 was predicted to target MRE11 and modulate CRC prognosis. The lower expression of miR-140 was associated with the metastatic phenotype (p < 0.05) and poor progression-free survival (odds ratio (OR) = 0.4, p < 0.05). In the in vitro analysis, we used miRNA mimics to increase the level of miR-140 in the CRC cell line. This resulted in decreased proliferation of CRC cells (p < 0.05). Increased levels of miR-140 also led to increased sensitivity of cancer cells to oxaliplatin (p < 0.05) and to the accumulation of DNA damage. Our results, both in vitro and in vivo, suggest that miR-140 may act as a tumor suppressor and plays an important role in DSB DNA repair and, consequently, CRC therapy response.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dolnikova, Alexandra $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Cumaogullari, Ozge $u Eastern Mediterranean University, Dr. Fazıl Küçük Faculty of Medicine, North Cyprus, Turkey $u Gazimağusa State Hospital, Molecular Genetics Research Laboratory, North Cyprus, Turkey
700    1_
$a Cumova, Andrea $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Navvabi, Nazila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u Biomedical Center in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia $u Biomedical Center in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Levy, Miroslav $u Surgical Department, 1.st Medical Faculty, Charles University and Thomayer Hospital, Prague, Czechia
700    1_
$a Schneiderova, Michaela $u Department of Surgery, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Liska, Vaclav $u Biomedical Center in Pilsen, Charles University, Pilsen, Czechia $u Department of Surgery, Medical Faculty in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Andera, Ladislav $u Institute of Biotechnology, Czech Academy of Sciences (CAS), Vestec, Czechia
700    1_
$a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia $u Biomedical Center in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Opattova, Alena $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), Prague, Czechia $u First Faculty of Medicine, Charles University, Prague, Czechia $u Biomedical Center in Pilsen, Charles University, Pilsen, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 959407
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36324569 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131202 $b ABA008
999    __
$a ok $b bmc $g 1889525 $s 1182848
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 12 $c - $d 959407 $e 20221017 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20230119
Back

Find record

Citation metrics

Archiving options